Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013889 | 1.00 | IDO1 (0.42) | IDO1MAOBCA1CA2KDM4E | |
| SCHEMBL7604498 | 0.84 | AGXT (0.44) | IDO1MAOBCA1CA2KDM4E | |
| SCHEMBL2408881 | 0.82 | IDO1 (0.42) | IDO1MAOBCA1CA2KDM4E | |
| SCHEMBL2408874 | 0.82 | IDO1 (0.42) | IDO1MAOBCA1CA2KDM4E | |
| SCHEMBL7863791 | 0.81 | TSHR (0.52) | CA1CA2L3MBTL1TDP1KMT2A | |
| SCHEMBL13002270 | 0.81 | TSHR (0.52) | CA1CA2L3MBTL1TDP1KMT2A | |
| SCHEMBL4545488 | 0.81 | TSHR (0.52) | CA1CA2L3MBTL1TDP1KMT2A | |
| SCHEMBL2406493 | 0.80 | IDO1 (0.38) | IDO1MAOBCA1CA2KDM4E | |
| SCHEMBL2406488 | 0.80 | IDO1 (0.38) | IDO1MAOBCA1CA2KDM4E | |
| SCHEMBL3790978 | 0.80 | IDO1 (0.35) | IDO1MAOBCA1CA2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | NOVARTIS AG (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-2271644-A1 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | NOVARTIS AG | 2010-10-07 | — | — | US | disclosed |
| EP-2212317-A1 | 4,4-DISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| EP-2212315-A1 | TRISUBSTITUTED PIPERIDINES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-7625893-B2 | Substituted 4-phenyl piperidines for use as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-01 | — | — | US | disclosed |
| WO-2009121914-A1 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | SPEEDEL EXPERIMENTA AG | 2009-04-02 | — | — | US | disclosed |
| EP-1934207-B1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| EP-1934207-A1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1911758-A1 | Phenyl piperidine derivatives for use as renin inhibitors | Speedel Experimenta AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008040764-A1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| EP-1908762-A2 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908763-A1 | Bicyclic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908761-A1 | Organic compounds | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908471-A1 | Tetrahydropyridines as renin inhibitors | Speedel Experimenta AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | REN, AGTR1, ACE | IDO1 3744/4885MAOB 451/4885CA1 3289/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | IDO1 3324/4885MAOB 1712/4885CA1 4675/4885 |
| US-20110212950-A1 | 4,4-DISUBSTITUTED PIPERIDINES | REN, AGTR2, AVPR2 | IDO1 3753/4885MAOB 891/4885CA1 4238/4885 |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | IDO1 3315/4885MAOB 796/4885CA1 4419/4885 |
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | REN, AGTR1, AGTR2 | IDO1 3878/4885MAOB 726/4885CA1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.